American Association for Cancer Research
00085472can142443-sup-136586_1_supp_2764256_nfr7yx.xlsx (3.08 MB)

Supplementary Table S4 from CLK2 Is an Oncogenic Kinase and Splicing Regulator in Breast Cancer

Download (3.08 MB)
posted on 2023-03-30, 23:32 authored by Taku Yoshida, Jee Hyun Kim, Kristopher Carver, Ying Su, Stanislawa Weremowicz, Laura Mulvey, Shoji Yamamoto, Cameron Brennan, Shenglin Mei, Henry Long, Jun Yao, Kornelia Polyak

Supplementary Table S4. List of genes differentially expressed following shCLK2 expression in MCF7 cells.



Genetically activated kinases have been attractive therapeutic targets in cancer due to the relative ease of developing tumor-specific treatment strategies for them. To discover novel putative oncogenic kinases, we identified 26 genes commonly amplified and overexpressed in breast cancer and subjected them to a lentiviral shRNA cell viability screen in a panel of breast cancer cell lines. Here, we report that CLK2, a kinase that phosphorylates SR proteins involved in splicing, acts as an oncogene in breast cancer. Deregulated alternative splicing patterns are commonly observed in human cancers but the underlying mechanisms and functional relevance are still largely unknown. CLK2 is amplified and overexpressed in a significant fraction of breast tumors. Downregulation of CLK2 inhibits breast cancer growth in cell culture and in xenograft models and it enhances cell migration and invasion. Loss of CLK2 in luminal breast cancer cells leads to the upregulation of epithelial-to-mesenchymal transition (EMT)-related genes and a switch to mesenchymal splice variants of several genes, including ENAH (MENA). These results imply that therapeutic targeting of CLK2 may be used to modulate EMT splicing patterns and to inhibit breast tumor growth. Cancer Res; 75(7); 1516–26. ©2015 AACR.

Usage metrics

    Cancer Research



    Ref. manager